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Abstract
In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the 
classification and management of acute kidney injury (AKI). The guideline was derived from 
evidence available through February 2011. Since then, new evidence has emerged that has 
important implications for clinical practice in diagnosing and managing AKI. In April of 2019, 
KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: 
determine best practices and areas of uncertainty in treating AKI; review key relevant literature 
published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify 
new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline 
research needed to improve AKI management. Here, we present the findings of this conference 
and describe key areas that future guidelines may address.
Keywords
acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement 
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In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on 
the classification and management of acute kidney injury (AKI).1 Since then, new evidence 
has emerged that has important implications for clinical practice. Large epidemiology 
studies and risk profiles for AKI have become available in adults and children, such as the 
AKI–Epidemiologic Prospective Investigation (AKI-EPI) study,2 the 0by25 Initiative,3 the 
Southeast Asia–AKI (SEA-AKI) study,4 and the Assessment of Worldwide Acute Kidney 
Injury, Renal Angina, and Epidemiology (AWARE)5 and Assessment of Worldwide Acute 
Kidney Injury Epidemiology in Neonates (AWAKEN)6 studies. The effectiveness of the 
KDIGO recommendations in preventing AKI has been confirmed in small single-center 
randomized controlled trials (RCTs), such as the Prevention of AKI (PrevAKI)7 and the 
Biomarker Guided Intervention for Prevention of AKI (BigpAK)8 studies. In addition, 
results of RCTs have provided new data relevant to several facets of preventing and 
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managing AKI, including early resuscitation, fluid therapy, prevention of contrast-associated 
AKI, and timing of acute renal replacement therapy (RRT).9–15 Finally, there is now 
evidence from large studies in different countries that the use of KDIGO criteria for AKI, 
as part of computer decision-support systems, can improve clinical outcomes.16,17 However, 
there has also been important progress in the development of new tools to diagnose and 
manage AKI, including biomarkers, decision support programs, and electronic alerts, that go 
beyond the current KDIGO definition/staging criteria, and these warrant consideration for 
inclusion in AKI guidelines.17–24
These advances are not without controversy. Adoption of new biomarkers has been 
heterogenous,25 and there are calls to revise KDIGO AKI staging based on creatinine and 
urine output,26 and even calls to discard the KDIGO staging completely.27 Thus, in April 
2019, KDIGO held a controversies conference entitled Acute Kidney Injury, in Rome, Italy. 
Participants examined and summarized evidence published since 2012 as it relates to the 
risk assessment, diagnosis, and management of patients with AKI and provided commentary 
on areas of controversy and agreement. The ultimate goals were to provide the clinical 
and research communities with a snapshot of the current state of the art for diagnosis and 
management of AKI and to prepare for future revision of the 2012 guideline.
NOMENCLATURE AND DIAGNOSTIC CRITERIA
AKI-related definitions
AKI and chronic kidney disease (CKD) are increasingly recognized as related entities 
representing a continuum of disease. The National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NKF-KDOQI) 2002 guideline and the 2012 KDIGO AKI 
guideline defined CKD as measured or estimated glomerular filtration rate (GFR) <60 
ml/min per 1.73 m2, or the presence of markers of kidney damage (e.g., albuminuria) 
for >90 days.1 The 2012 KDIGO guideline defined AKI as an abrupt decrease in kidney 
function occurring over 7 days or fewer (Table 1).1 To complete the continuum, the 2012 
guideline proposed the term acute kidney diseases and disorders (AKD) to define conditions 
of impaired kidney function not meeting the criteria for either AKI or CKD but having 
adverse outcomes and requiring clinical care. However, consensus on the exact criteria and 
indicators of severity is urgently needed.
Because the diagnosis of AKI should be tied to management decisions, and because 
changing disease definitions may have major implications for disease epidemiology, the 
case for revising the 2012 KDIGO definition of AKI should be strong before changes are 
proposed. Furthermore, in the context of an AKI guideline revision, several classification 
systems in addition to the stages of AKI should be rigorously defined. These relate to the 
distinctions among persistent, transient, relapsing, and recovered AKI; various etiologies 
of AKI; and community-onset versus hospital-onset AKI. In addition, there is emerging 
evidence that markers of structural kidney damage may be associated with clinically relevant 
outcomes and therefore identify potentially actionable entities. For an AKI guideline 
revision, the evidence base should be reviewed to determine whether markers of kidney 
damage constitute risk factors for AKI, define a new entity (such as subclinical or preclinical 
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AKI), or should be incorporated into the AKI definition. Finally, the future guideline should 
use nomenclature that is precise and patient-centered.
The clinical importance of AKD needs to be further assessed. Retrospective cohort data 
based only on changes in serum creatinine values and with limited clinical context suggest 
a relevance for AKD: the population of patients who meet laboratory criteria for AKD but 
not CKD or AKI is relatively large, and these individuals have increased risks of incident 
and progressive CKD, kidney failure (formally referred to as “end-stage kidney disease”), 
and death,28 confirming the need to better define and classify AKD. Furthermore, a revised 
definition and classification of AKD could be better harmonized with both the definitions 
and classifications of AKI and CKD and tie to clinical management. As in adults, the 
AKI/AKD/CKD spectrum should be unified in children, and definitions should be the same 
for children and adults. A special consideration in children, as well as in adults with low 
muscle mass, is a reduced serum creatinine concentration, which may impact AKI diagnosis.
The assessment of renal recovery is still controversial, and its definition is essential given 
the implications for patients and clinicians. Issues related to assessment of recovery include 
changes in creatinine generation due to reduction in muscle mass, among others.
Advances in diagnosis of AKI
Serum creatinine and urine output continue to be the foundational measures for AKI 
diagnosis even though their limitations are well known. In the future, kidney damage 
biomarkers, biopsy, and imaging may be useful for staging AKI, classification of cause, 
prognosis, and treatment. However, currently there is insufficient information about any of 
these measures to warrant addition to the AKI definition. Given that the global availability 
of novel biomarkers is limited, incorporating them into definitions will be challenging. 
Measurements of real-time or kinetic GFR are research tools at present, and more evidence 
is needed regarding their clinical applicability (Table 2).
Both urine output and serum creatinine level should continue to be used29; ideally, the new 
AKI guideline would provide further clarification as to the role of these measurements. If 
possible, both should be ascertained. However, if serum creatinine measurements are not 
immediately available, urine output criteria should be used.
It remains unclear how to best determine baseline kidney function. What constitutes a 
baseline serum creatinine level is controversial and inconsistently defined. It would be ideal 
to have prior serum creatinine or GFR measurements widely available through electronic 
medical records, but this is not current practice in many parts of the world. Prior serum 
creatinine or GFR measures may also further elucidate the risk of AKI in patients considered 
at high risk on the basis of either comorbidity or an intervention. There is controversy about 
whether an acute decrease in serum creatinine level indicates AKI that has already occurred, 
and more research is needed in this area. For example, small declines in serum creatinine 
level need to be interpreted with caution because they may be the result of acute changes 
in creatinine production or volume of distribution. After a timed insult (e.g., coronary 
angiography, elective surgery, nephrotoxic drug exposure), serum creatinine level should be 
measured at an appropriate time, allowing for AKI to manifest. After AKI onset, serum 
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creatinine level should be measured during follow-up as necessary for clinical management 
and care transitions (e.g., transfer to and from intensive care) and for determining changes in 
AKI staging and classification (AKI vs. AKD), including onset of CKD at 90 days.
How urine output should be evaluated is also an area that needs further investigation to 
avoid variability in reporting of AKI incidence (i.e., use of actual or ideal body weight, strict 
time period vs. time-averaged values).30 Future guidelines should address how differences 
in body composition (overweight, fluid overload) affect the interpretation of urine output, 
and whether these differences need to be considered in regard to the thresholds for AKI. 
Similarly, fluid status should be considered when evaluating for AKI. Fluid overload is 
associated with increased mortality and AKI, and it may impact the diagnosis of AKI 
through its impact on the volume of distribution of serum creatinine. Although there are 
research methods to define fluid overload, these are not routinely used in clinical practice, 
and it is unclear whether there is sufficient evidence to define a clinical threshold for fluid 
overload. In the next AKI guideline, fluid overload should be defined operationally through 
a rigorous literature review.
AKI RISK STRATIFICATION AND ASSESSMENT
Risk stratification
In community and hospital settings, risk stratification of patients using a combination of 
baseline risks and acute exposures is important.31 In the future, risk stratification could 
incorporate various clinical contexts: geographic region, onset in community or hospital 
settings, and location within hospitals. Although the 2012 guideline discussed risk models 
and clinical scores, these were limited to models for cardiothoracic surgery, contrast 
exposure, and aminoglycoside administration. Many other clinical scenarios and contexts, 
such as sepsis and cardiac failure, require guidance for risk assessment. In clinical practice, 
risk models may be tailored for location and context. Multicenter studies are needed for 
externally validating models as well as standardization and correlation with outcomes. 
Furthermore, since 2012, biomarkers for AKI risk stratification have been approved by 
the US Food and Drug Administration (https://www.accessdata.fda.gov/cdrh_docs/reviews/
DEN130031.pdf) and integrated in recent guideline recommendations for cardiac surgery.32
Determining cause and prognosis
Determining the etiology of AKI is essential for management; however, this can be difficult, 
especially in the presence of multifactorial mechanisms. Newer developments related 
to monitoring and evaluating risk progression include e-alert systems, machine-learning 
algorithms and artificial intelligence for AKI recognition and monitoring,20,33–36 as well 
as models based upon the renal angina index,37,38 furosemide stress test (FST),39 or 
biomarkers.40–43 In revisiting the guideline for AKI, severity of AKI should be based not 
only upon serum creatinine elevation and urine output, but also upon duration, possibly with 
the inclusion of biomarkers. The need to increase attention for persistent (>48 hours) AKI 
should also be considered.44
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The 2012 KDIGO guideline suggests performing a kidney biopsy when the cause of AKI 
is unclear. Potential benefits for biopsy in AKI are controversial and further research is 
needed.45 Since the 2012 guideline, which recommended ultrasound for assessing kidney 
size and the presence of an obstruction, new imaging techniques have become available, 
such as contrast-enhanced ultrasound, doppler ultrasound, and blood oxygenation level—
dependent functional magnetic resonance imaging.46–48 The role of these techniques in 
changing outcomes of AKI is yet to be determined.
The 2012 KDIGO guideline recommended urine sediment analysis for differential diagnosis 
in patients with AKI, especially when glomerular disease is expected. Meeting participants 
noted that urine sediment analysis is not routinely performed in many centers despite its 
potential role in the workup of AKI.49,50 Additionally, the value of urine biochemistry 
analysis has been challenged, especially in sepsis.51
The FST may be useful for identifying patients with AKI who are likely to have progressive 
disease and need dialysis.52 There is also evidence that the FST is useful in predicting 
delayed graft function following deceased donor kidney transplantation.53 This test was 
not included in the 2012 guideline but should now be considered. Importantly, unregulated 
diagnostics tests such as FST or urine sediment analysis require careful standardization and 
quality control. Their introduction into clinical practice should include local evaluation for 
correct performance and interpretation.
The traditional approach to classifying AKI as pre-renal, renal, and post-renal is still 
found in many medical text-books. A different framework is needed, because these terms 
are considered unhelpful, especially the term pre-renal, which is often misinterpreted as 
“hypovolemic” and may encourage indiscriminate fluid administration. For classifying AKI, 
it may be more beneficial to distinguish between conditions that reduce glomerular function, 
conditions that result in injury of tubules and/or glomeruli, and conditions that do both.
Endpoints for clinical trials and quality improvement initiatives for AKI include mortality, 
new onset or progression of CKD, and dialysis dependency. Additional endpoints are needed 
for both clinical management and research, and these might include recovery of function, 
maximum changes in creatinine concentration, stage of AKI/AKD, impact on renal reserve, 
and patient experience. Additionally, there is a need to better define renal recovery and its 
functional (filtration, tubular, endocrine) and anatomic/structural dimensions.
Follow-up
Increased risks for mortality, cardiovascular events, and progression of kidney disease 
are well-documented outcomes of AKI.28,54–56 However, not everyone with AKI has 
a poor outcome, and predictors of poor outcomes have been identified.57 Follow-up 
recommendations (Figure 1)31 have been proposed that could be integrated into a KDIGO 
guideline revision. Although it has been suggested that patients be screened at hospital 
discharge or seen within 1 month of AKI diagnosis,58 there is no consensus on the optimal 
strategy and duration of follow-up to improve short- and long-term outcomes.
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FLUID MANAGEMENT AND HEMODYNAMIC SUPPORT
Timing of fluid administration
Ensuring adequate hydration and volume status is essential in preventing and treating AKI. 
Oral or i.v. fluid may be administered depending on the local environment and clinical 
context. The administration of i.v. fluids should be guided by hemodynamic assessment for 
specific indications and contraindications. When deciding on fluid therapy, consideration for 
the clinical context and history, including timing of the insult, is critical. Table 3 lists clinical 
contexts in which indications for fluid administration should be balanced against potential 
coexisting conditions that require a more cautious approach. Because both the physiological 
response to fluids and the underlying condition related to AKI are dynamic over time, fluid 
administration should be based on repeated assessment of overall fluid and hemodynamic 
status and dynamic tests of fluid responsiveness.59,60
There continues to be concern about excessive fluid administration for hypotension, and 
earlier use of vasoactive medications may be appropriate for some patients.61,62 The effect 
of these strategies on kidney function is not clearly defined and likely to be context 
specific.63 Ongoing major multicenter RCTs examining kidney endpoints are evaluating 
fluid administration and vasoactive medications, and their results are likely to impact AKI 
treatment recommendations.
Methods of fluid administration
Significant new evidence from several large multicenter RCTs regarding use of protocolized 
goal-directed fluid therapy in early septic shock has suggested lack of benefits for survival 
and kidney outcome.64–66 However, there is some evidence to suggest that goal-directed 
protocols have benefits in perioperative patients.67,68 Therefore, recommendations regarding 
goal-directed fluid therapy for preventing or treating AKI may emerge to become more 
context specific. Additionally, clinical fluid therapy targets have evolved to include more 
dynamic indices, including the passive leg-raising test, pulse/stroke volume variation, 
and parameters derived from ultrasound. However, there is limited evidence that specific 
physiological targets for fluid therapy improve kidney outcomes.
Composition of i.v. fluid preparations
Crystalloids.—Evidence of biochemical abnormalities and adverse clinical outcomes 
associated with 0.9% saline compared with more physiological crystalloids (e.g., lactated 
Ringer’s) has continued to accumulate since 2012.11,12 Results from two large ongoing 
multicenter RCTs (NCT02875873, NCT02721654) are awaited. This evidence will require 
careful evaluation to provide the community with a new consensus regarding the magnitude 
of risks associated with 0.9% saline in acute illness and surgery, including considerations for 
resource-limited settings in which alternatives may be limited.
Synthetic colloids.—In recent years, consensus has emerged that due to the increased 
incidence of kidney dysfunction and mortality, synthetic colloids are harmful in critically 
ill patients, especially those with sepsis.69,70 However, whether these risks also apply to 
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perioperative patients remains controversial, and this question is being examined in ongoing 
trials.
Albumin.—In RCTs, the use of albumin (including hyper-oncotic solutions) has not been 
shown to be harmful to kidney or other outcomes.71,72 However, clear evidence of benefit is 
also lacking, and any benefits may be limited to specific patient populations.73–75
Fluid removal
Physiological and epidemiologic evidence indicates that volume overload and venous 
congestion have adverse effects on kidney function and outcomes in both acute and chronic 
illness.76–78 In children, there is evidence that >10%–15% fluid overload by body weight is 
associated with adverse outcomes.79,80 However, the method for determining fluid overload 
and the threshold for clinically significant fluid overload in adults are not well defined, 
nor is the precise role of timing of fluid removal on kidney function and other outcomes. 
Therefore, there is a need to develop a consensus around methods and thresholds for fluid 
overload evaluation in adults and to establish recommendations for its management (Table 
2).
NEPHROTOXIC AGENTS AND DRUGS THAT AFFECT KIDNEY FUNCTION
The use of drugs associated with kidney injury or dysfunction is common both in 
the hospital setting and in the community for patients with chronic illnesses such as 
hypertension, congestive heart failure, diabetes mellitus, cancer, and CKD. These drugs 
are often referred to as “nephrotoxic,” although many of them lead to kidney dysfunction 
without direct glomerular or tubular cell damage. Furthermore, some drugs that may 
cause a rise in serum creatinine are actually reno-protective and associated with improved 
outcomes (i.e., angiotensin-converting enzyme inhibitors or sodium-glucose co-transporter-2 
inhibitors81 in diabetic nephropathy). Although it would be ideal to propose a simple yet 
inclusive term to encompass the various mechanisms by which drugs interface with the 
kidney, meeting participants were unable to identify one. Thus, here the term “nephrotoxic 
drugs” is retained for consistency with the literature. A new classification should also 
encompass drugs that are not directly harmful to kidney function but are eliminated by the 
renal route, and where there is concern about harm from accumulation of parent drug or 
metabolites in the setting of AKI and AKD. Similarly, failure to increase drug doses and 
intervals in renal recovery or with enhanced elimination via extracorporeal clearance may 
lead to therapeutic failure.82
In the past 10 years, significant progress has been made regarding susceptibility, 
management, and preventive strategies to avoid or ameliorate drug- and drug combination–
associated kidney injury and dysfunction more broadly.
Overarching nephrotoxic medication management considerations are as follows:
• Patients should receive potentially nephrotoxic medications only if needed and 
only for as long as needed.
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• Potentially nephrotoxic agents should not be withheld in life-threatening 
conditions, owing to concern for AKI, including i.v. contrast.
• Kidney function must be monitored in patients who are exposed to agents that 
are associated with kidney injury or dysfunction, to limit the risk and progression 
of AKI and AKD.
• Patients and clinicians need appropriate and effective education as to the 
potential for kidney injury and dysfunction from nephrotoxic agents.
Classifying drugs that affect kidney function and/or are nephrotoxic
There are multiple mechanisms by which drugs affect the kidney. They are summarized 
in 2 major categories: systemic or renal/glomerular hemodynamic effects (i.e., kidney 
dysfunction); and tubular or structural damage (i.e., kidney injury). Kidney dysfunction 
can result from drugs that lead to systemic hypotension (e.g., systemic arterial vasodilation) 
and/or altered intraglomerular hemodynamics (e.g., afferent arteriole constriction, efferent 
arteriole dilation). As a result, renal perfusion pressure is decreased, and if the decrease is 
sustained or severe, it can lead to ischemic injury. In comparison, drug-associated kidney 
injury is characterized by glomerular or tubular cell injury triggered by filtered toxins, 
tubular obstruction, endothelial dysfunction, or an allergic reaction.83–85 Important to note is 
that a given drug may lead to both dysfunction and injury.
A useful framework for classifying the mechanisms of drug-induced kidney injury or 
dysfunction is depicted in a 2x2 table to classify functional, structural, and combined 
functional/structural AKI86 (Figure 2). Drugs can affect the kidney by each of these 
mechanisms, and the figure depicts susceptibilities for AKI, as well as accelerants to develop 
dysfunction or injury and transition to dysfunction and injury. An important aspect of 
the framework is consideration of risk-mitigation strategies. Currently, there is sufficient 
evidence to classify drugs that affect kidney function or are nephrotoxic, in a clinically 
useful way.87,88
Preventing and mitigating drug-associated AKI
A number of strategies have emerged for preventing or mitigating drug-associated kidney 
injury or dysfunction. The most important of these is drug stewardship,21,89,90 with a 
primary goal of balancing the changing risks and benefits of drug utilization and dosing in 
AKI/AKD (Table 4).82 Specifically, it is critical to balance the risk of toxicity caused by 
excessive doses or drug/metabolite accumulation in AKI/AKD versus the risk of therapeutic 
failure caused by either overly conservative drug avoidance or under-dosing, or the risk of 
failing to adapt to renal recovery or use of renal replacement therapy (RRT).
Recent literature has demonstrated that certain drug combinations and overall drug burden 
are associated with AKI.91 These include the “triple whammy” of renin–angiotensin system 
inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs, and an increased AKI risk 
when patients receive 3 or more nephrotoxic drugs daily.92 A single center has utilized 
electronic health records to identify children exposed to 3 or more nephrotoxic drugs, and 
the approach has led to a sustained decrease in incidence of AKI.21
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Preventing and managing contrast-associated AKI
The only nephrotoxic agent addressed in any detail by the 2012 KDIGO AKI guideline was 
iodinated radiocontrast media.1 The 2012 guideline included several recommendations to 
prevent contrast-induced AKI, including use of volume expansion with sodium bicarbonate 
solutions and oral N-acetylcysteine. Results of the Prevention of Serious Adverse Events 
Following Angiography (PRESERVE) and POSEIDON trials demonstrated lack of efficacy 
of these interventions (and instead found improvement using a personalized approach 
targeting cardiac filling pressures in POSEIDON).93,94 Furthermore, recent evidence 
suggests that the risks associated with i.v. contrast are far fewer with modern agents and 
practice patterns, and significant kidney injury is unusual in patients with normal or mildly 
reduced baseline kidney function.95 I.v. contrast should not be withheld owing to concern for 
AKI in life-threatening conditions in which the information gained from the contrast study 
could have important therapeutic implications.
RENAL REPLACEMENT THERAPY
RRT terminology and initiation
In recent years, the suggestion has been made that the English term “renal” should 
be replaced by “kidney,” because the latter is more familiar to most English speakers. 
Additionally, the term “replacement” may not be sufficient, and terms such as “support” or 
“partial replacement” may be more accurate. The implications of changes in nomenclature 
are not insignificant. Additionally, the distinction between kidney versus renal does not 
apply in all languages. Accordingly, KDIGO has convened a separate Nomenclature 
Consensus Conference for the purpose of recommending nomenclature consistent with 
guidelines for acute and chronic kidney disease.96 Above all, patients should be the focus 
of all communication and care. Whenever possible, all decisions about treatment should 
be shared with patients, their families and/or next of kin, and if required, all members 
of the end-of-life care multidisciplinary team. All communication with patients and their 
supporting families/friends should be provided in simple lay language at regular intervals, 
with the awareness that patients may be traumatized. “Life support,” “kidney machine,” or 
similar words are preferred to the term RRT. If RRT becomes permanent, and the patient 
enters the chronic dialysis pathway, all relevant medical or nursing personnel should change 
their language to specify the type of RRT (transplant, hemodialysis, or peritoneal dialysis).
The 2012 KDIGO AKI guideline suggested initiating RRT emergently in the presence of 
life-threatening changes in fluid, electrolyte, and acid–base balance. Since 2012, data from 
several RCTs and observational studies have become available.13–15,97–104 However, the 
optimal timing for acute RRT remains unknown. It has been proposed that initiation of 
RRT should be considered when metabolic and fluid demands exceed the kidney’s capacity 
to meet them.105–107 This concept acknowledges the dynamic nature of acute illness and 
stresses the importance of regular evaluation of the demand and renal capacity relationship. 
However, the exact methods for determining demand and capacity are unknown. Existing 
evidence does not support using biomarkers when deciding whether to initiate RRT.13,97,108 
Use of a standardized FST can be considered in AKI, to further quantify the likelihood of 
AKI progression, and integrated into the spectrum of clinical information available when 
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planning for and deciding to initiate RRT.39,52,109,110 In determining whether or not to start 
RRT, risk of complications, global prognosis, potential for recovery, and patient preferences 
should be considered (Figure 3). Although some regions of the globe have challenges and 
constraints in providing universal access to RRT,111 we recommend a similar approach 
be undertaken for considering for whom and when to start RRT in all regions.112–114 
Additionally, a similar approach should be undertaken in both intensive care unit and non–
intensive care unit settings.
Providing RRT
Although the timing of RRT initiation is controversial, the provision of RRT itself has 
become fairly well established. Patients with AKI requiring RRT have an evolving clinical 
status and should be supported by the appropriate and available modality. Modality choice 
should also be tailored to patient clinical status. As suggested in the 2012 KDIGO 
guideline, in hemodynamically unstable patients, continuous RRT, rather than intermittent 
hemodialysis, is more physiologically appropriate, but RCTs have not demonstrated better 
outcomes with continuous RRT.1 Both continuous and intermittent RRT can lead to changes 
in intracranial pressure, but the risk is higher with intermittent RRT. Selection of modalities 
should be considered in the context of available resources and expertise of personnel.
An uncuffed non-tunnelled dialysis catheter of appropriate length and gauge should be used 
to initiate RRT in AKI patients. In patients with expected prolonged indication for RRT, a 
cuffed catheter can be considered.115 The first choice for site is the right jugular vein or 
femoral vein, although the femoral site is inferior in patients with increased body mass. The 
next choices would be left jugular vein followed by subclavian vein. Anticoagulation type 
should be selected based on local resources and expertise of personnel. The recommendation 
from 2012 to use regional citrate anticoagulation for continuous RRT in patients who do 
not have a contraindication remains supported by existing data.116–118 Delivery of RRT 
must reach the goals of electrolyte, acid–base, solute, and fluid balance for each specific 
patient.119 When using intermittent or extended RRT, a Kt/V of at least 1.2 per treatment 3 
times a week should be delivered.120 For peritoneal dialysis, future studies should focus on 
dosing in AKI, although currently we suggest a dose of 0.3 Kt/V per session. An effluent 
volume of 20–25 ml/kg per h should be delivered when continuous RRT is used. This 
will sometimes require a higher prescription of effluent volume.121,122 The rate of fluid 
removal for a given patient with fluid overload is controversial,123,124 and more research 
is needed. Methods to better assess fluid management goals during RRT would also be 
valuable. Finally, RRT should be discontinued when kidney function has recovered or when 
RRT becomes inconsistent with shared care goals. Modality transition from continuous 
RRT to intermittent hemodialysis in intensive care unit patients should be considered when 
vasopressor support has been stopped, intracranial hypertension has resolved, and positive 
fluid balance can be controlled by intermittent hemodialysis.
RRT in the context of multi-organ support
The 2012 KDIGO AKI guideline did not address utilization of extracorporeal life support 
(ECLS) such as extracorporeal membrane oxygenation (ECMO), extracorporeal carbon 
dioxide removal (ECCO2R), and left or right ventricular assist device. Several issues remain 
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unresolved: the optimal approach to patient selection, techniques, and timing/indications; 
circuit integration; and monitoring for ECLS and concomitant blood-purification techniques. 
Several observational studies on this theme warrant analysis and interpretation.125–131
Decisions regarding how to combine RRT with ECLS devices will depend on local 
expertise, technology, and human resources. Such combined treatment should be based on 
a multidisciplinary approach to patient care and shared decision-making. More studies are 
needed to define the best strategy for training and practice.
Although different RRT modalities can be used to support patients during ECLS, and 
comparative studies are not available, because of hemodynamic status, continuous RRT 
is more appropriate in this setting. It would be useful to develop a registry focused on 
patients receiving ECLS-RRT, to understand the epidemiology, technology, indications, and 
complications associated with current practice.
There is no clear evidence that usual RRT indications should vary according to the 
presence or absence of an ECMO/ECCO2R circuit. Nonetheless, patients for whom ECMO 
or ECCO2R is required are very sensitive to fluid overload. Therefore, in patients with 
versus without ECMO/ECCO2R, earlier RRT may be required for preventing and managing 
fluid overload. A registry of patients combining ECMO/ECCO2R and RRT could improve 
understanding of current practice for initiating RRT in patients (adults and children) with 
ECMO/ECCO2R and fluid management. Respiratory dialysis (ECCO2R and ECMO) with 
modified dialysis solutions is currently limited to in vitro and experimental studies,132–134 
and research focused on this technical aspect is needed.
The anticoagulation of RRT circuits when ECMO/ECCO2R is already running is not 
standardized. The administration of heparin may depend on patient factors (e.g., risk 
of bleeding), circuit set-up (e.g., connection to patient or to ECMO), and institutional 
protocols.128,130,135–141 It is possible to have RRT circuits without dedicated heparin 
in this setting, unless excessively frequent clotting is observed. Studies are needed to 
compare different anticoagulation strategies in this setting. Citrate anticoagulation during 
RRT added to ECMO/ECCO2R is possible.139,140 Its feasibility and performance compared 
with other forms of anticoagulation remain untested, and thus comparative studies of citrate 
anticoagulation are recommended.
RRT long-term outcomes and follow-up
Choice of RRT modality and impact on recovery.—The selection of RRT modality 
does not appear to have a major impact on recovery of kidney function.141–143 Selection of 
modality of RRT should therefore be based on shared decision-making, local expertise, 
logistic factors, and patient characteristics. Estimated GFR in conjunction with major 
adverse kidney events has been used for medium- and long-term assessment but has several 
limitations. There is uncertainty about the best way to measure renal recovery after RRT in 
both the short- and medium-term. However, proteinuria is associated with worse long-term 
outcomes and is easy to measure.
Ostermann et al. Page 12













Assessment of kidney function for renal recovery.—In addition to the development 
of CKD, patient-centered outcomes (quality of life, functional recovery), along with patient 
experience after AKI, should be a priority and need to be assessed. Post-AKI proteinuria is 
associated with future loss of kidney function and is regarded as a valuable risk-stratification 
tool in the post-AKI period.144–146
Optimal follow-up for AKI patients following RRT
Shared decision-making and communication among caregivers, the patient, and family 
members is crucial to patient recovery. Patients recovering from critical illness and AKI 
are often discharged to rehabilitation/skilled nursing facilities and need close monitoring to 
ensure adequate overall recovery to a baseline state of health and well-being. Such patients 
should receive multidisciplinary, recovery-focused care. Patients with AKI who continue to 
require RRT at hospital discharge often receive hemodialysis in outpatient dialysis facilities. 
Patients with congestive heart failure are less likely to recover kidney function.147 Higher 
ultrafiltration rates and more intradialytic hypotensive episodes are associated with higher 
risk of non-recovery of kidney function.148,149 To assess for renal recovery, hemodynamic 
status, intravascular volume, and urine output during dialysis should be carefully monitored.
Quality indicators for acute RRT
The importance of measuring and monitoring the quality of acute RRT provided to critically 
ill patients with AKI, including the optimal “benchmarking” for acute RRT programs, is 
receiving great attention.119,150 Quality of acute RRT should be monitored to ensure the 
effective and safe delivery of care.151 At a minimum, institutions and programs providing 
RRT should integrate, monitor, and report quality and outcome indicators across all forms of 
acute RRT therapies.31 These outcome measures should comprise a variety of metrics that 
incorporate patient survival, patient-centered acute RRT outcomes, safety, AKI survivor–
related outcomes, and patient experience. Quality indicators should include shared goals that 
are patient- and clinically centered.
CONCLUSIONS
Although much of the 2012 KDIGO AKI guideline remains state of the art, advances over 
the past decade have improved our understanding of best practices. Many of these advances 
are widely accepted (e.g., nephrotoxic medication stewardship, shared decision making for 
RRT), but others are more controversial (Table 5). Although some centers and specific 
programs have embraced new technologies and ways of thinking, others have taken a more 
conservative, or “wait-and-see” approach. Even among conference participants, there was 
lack of unanimity for various perspectives, and obvious practice variation continues to exist, 
even among experts. Perhaps more than any new trial or discovery, this fact provides ample 
rationale for revisiting the AKI guideline in the near future.
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Figure 1 |. Schematic for acute kidney injury/acute kidney diseases and disorders (AKI/AKD) 
follow-up.
The figure displays a potential paradigm for the care of patients who experience AKI/
AKD. The degree of nephrology-based follow-up increases as the duration and severity 
of AKI/AKD increases. The timing and nature of follow-up are suggestions, as there are 
limited data to inform this process. Future research efforts should work to clarify the timing 
of AKI/AKD follow-up and which specific healthcare providers should provide it. The items 
in each bucket follow the “OR” rule; therefore, each patient should follow the most-severe 
bucket even if they meet only 1 criterion in that bucket. For example, a patient with CKD 
G4, regardless of severity of AKI, should be followed by a nephrologist in 1 week. AKI 
stage 3D, AKI stage 3 treated by dialysis; CKD, chronic kidney disease; CV, cardiovascular; 
dx, diagnosis; KAMPS, kidney function–advocacy–medications–pressure–sick day protocol; 
SCr, serum creatinine; UA, urine analysis; WATCH-ME, weight assessment–access–
teaching–clearance–hypotension–medications. Reproduced with permission under a Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0) from Acute 
Dialysis Quality Initiative. Quality improvement goals for acute kidney injury; ADQI XXII. 
Available at: https://www.adqi.org/Images_Charts-Call.htm. Accessed June 14, 2020.31
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Figure 2 |. Classifying drugs that potentially cause acute kidney injury.
Iterative classification of agents that have potential to cause kidney dysfunction or kidney 
injury or both. Functional and injury biomarkers have a role in distinguishing among 
the different pathophysiological processes. Examples of deleterious risk modifiers are 
duration of therapy, drug burden, hypotension, and pharmacokinetic/pharmacodynamic 
interactions. Examples of interventions to mitigate risk are daily dynamic prescribing, 
kidney monitoring, and patient and provider education. Susceptibility factors include those 
listed in the 2012 Kidney Disease: Improving Global Outcomes Acute Kidney Injury 
guideline: dehydration or volume depletion; advanced age; female gender; black race; 
chronic kidney disease; chronic diseases of the heart, lung, or liver; diabetes mellitus; 
cancer; and anemia.1 Any final impact depends on underlying susceptibility, associated 
risk factors, clinical context, drug management, and modifying factors. Examples of drugs 
that correspond to the relevant categories above include trimethoprim, cimetidine (neither 
dysfunction nor injury); angiotensin-converting enzyme inhibitors, angiotensin-receptor 
blockers (dysfunction without injury); aminoglycoside, acyclovir, vascular endothelial 
growth factor antagonists (injury without dysfunction); and nonsteroidal anti-inflammatory 
drugs (dysfunction and injury).
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Figure 3 |. 
Schematic diagram of renal replacement therapy (RRT) decisions in acute kidney injury 
(AKI).
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Table 4 |
Strategies for a drug stewardship program focused on AKI/AKD
• Include a clinical pharmacist for drug stewardship.
• Identify patients at risk of AKI/AKD and take into account the risk of AKI/AKD when prescribing.
• Assess hydration status.
• Assess chronic drugs and their indication for continuation or discontinuation.
• Perform medication regimen review and evaluate PK/PD interactions.
• Review the use of drugs in patients who develop acute or chronic illnesses that increase the risk of AKI.
• Assess the dynamic impact of AKI/AKD on drug PK/PD.
• Assess the dynamic impact of renal recovery on drug PK/PD.
• Assess concurrent illness on drug PK/PD (e.g., sepsis, heart failure).
• Assess the impact of RRT on drug PK/PD.
• Undertake dynamic prescription and medication reconciliation at transitions of care.
AKD, acute kidney diseases and disorders; AKI, acute kidney injury; PD, pharmacodynamics; PK, pharmacokinetics; RRT, renal replacement 
therapy.
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